Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-My ers Squibb/Pfizer), a direct oral factor Xa inhibitor, was &approved for use in the 27 EU member states. The w orld's first drug approved to prevent venous thrombo♥embolism (VTE) in adult patients undergoing elective ↕hip or knee replacement. From June 2019 to June 202®0, the annual sales of apixaban products overseas reached about $15.4 billion, with a ≠year-on-year growth of nearly 32%, and the API consumption rea♦ched about 23,960 kg, with a year-on-year growth of about 28%. Com™pared with its main competitor, Rivaroxaban, the drug's ann±ual overseas sales are about $4.5 billion higher.

key word:

consumption apixaban

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry• finance platform company integrating pharmaceutical, §intelligent medical, bio pharmaceutical R&D, industri×al production and sales.

The chemical reactions involved in the existing produc×ts include Foucault reaction, nitration reaction, su↕lfonation reaction, hydrogenation reaction, fluorination reaction, chl×orination reaction, bromination reaction, diazotization reaction, format reaction, etc.

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer)♠, a direct oral factor Xa inhibitor, was approved for use i‍n the 27 EU member states. The world's first drug approved to preven‍t venous thromboembolism (VTE) in adult patients undergoing elective hip or knλee replacement. From June 2019 to June 2020, the annual sales of apixaban products overseas r→eached about $15.4 billion, with a year-on-year growth of nearly 32%, and the ≠API consumption reached about 23,960 kg, with a year-on-year growth of about 28%. Compared with it♦s main competitor, Rivaroxaban, the drug's annual overseas sales ↓are about $4.5 billion higher.

Apixaban and rivaroxaban have their own advantages, and sales are on φthe rise. Apixaban is the third new oral anticoagulant to hit the market.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (←DPP4) inhibitor developed by Merck. In October 2006, Sitagliptin pπhosphate Januvia was approved by FDA as the first DPP4 inhibitor for the treatment  of type ⅱ diabetes mellitus. The characteristics of this drug are that it can stimul ate insulin secretion while reducing hunger without causing weight gain. Hypoglycemia aαnd edema will not occur, and it is suitable for diabetic patients with poor blood  glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceuticaΩl enterprise that is market-oriented and realizes ♠industrial development through R&D innovation and technology tran÷sformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most im$portant products for the treatment of arthritis. It is well tolerated and has a low λincidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor a♠ntagonists. In clinical application, it has good the®rapeutic effect on atopic asthma and other types of bronchial asthma, and the market prospect is∏ huge. In the major category of asthma drugs, leukotriene receptor antagonists have the fastest gr↓owing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech ph↑armaceutical enterprise that is market-oriented and realizes industrial development through R✔&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FβDA for Alzheimer's disease in the United States. Its treatment reaches the§ target dose and has low toxic and side effects. It ha♦s been widely recognized by our medical community, and good tolerance is it&s biggest advantage. In October 1999, Donepezil was launched in China under t∞he trade name "Aricept", which is the main chemical↓ drug against Alzheimer's disease. At present, CFDA has approved a¥ number of domestic enterprises to produce donepezil preparations, the main do✘sage forms are tablets, capsules, dispersive tablets, oral di÷sintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squi∏bb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member states. ↓The world's first drug approved to prevent venous thromboembo↕lism (VTE) in adult patients undergoing elective hip or knee replacement. From June 2019 to ↔June 2020, the annual sales of apixaban products overseas reached about $15.4 bi↕llion, with a year-on-year growth of nearly 32%, and the API consumption reached about 23,9γ60 kg, with a year-on-year growth of about 28%. Compared with its main competi♣tor, Rivaroxaban, the drug's annual overseas sales are about $4.5✔ billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical ente>rprise that is market-oriented and realizes industrial development through R&D£ innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactu​red by Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refra ctory or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is m®arket-oriented and realizes industrial development through R&D innovation and↑ technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). I±f you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.